

# CITATION REPORT

List of articles citing

Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?

DOI: 10.1016/j.jval.2014.01.010  
Value in Health, 2014, 17, 438-44.

**Source:** <https://exaly.com/paper-pdf/59636656/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
38	Prospects of risk-sharing agreements for innovative therapies in a context of deficit spending in Bulgaria. <i>Frontiers in Public Health</i> , <b>2015</b> , 3, 64	6	9
37	Definition and Classification of Intraoperative Complications (CLASSIC): Delphi Study and Pilot Evaluation. <i>World Journal of Surgery</i> , <b>2015</b> , 39, 1663-71	3.3	71
36	How do we value a cure?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2015</b> , 15, 551-5	2.2	8
35	When do performance-based risk-sharing arrangements make sense?. <i>European Journal of Health Economics</i> , <b>2015</b> , 16, 569-71	3.6	11
34	Clinical players and healthcare payers: aligning perspectives on the cost-effectiveness of next-generation sequencing in oncology. <i>Personalized Medicine</i> , <b>2015</b> , 12, 9-12	2.2	4
33	Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. <i>Regenerative Medicine</i> , <b>2015</b> , 10, 897-911	2.5	36
32	Financing a Cure for Diabetes in a Multipayer Environment. <i>Value in Health</i> , <b>2016</b> , 19, 861-868	3.3	9
31	Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell Product. <i>Cell Stem Cell</i> , <b>2016</b> , 18, 436-7	18	13
30	Sustainable Financing of Innovative Therapies: A Review of Approaches. <i>Pharmacoeconomics</i> , <b>2016</b> , 34, 971-80	4.4	12
29	Making economic evaluations more helpful for treatment choices in haemophilia. <i>Haemophilia</i> , <b>2017</b> , 23, e58-e66	3.3	7
28	Gene therapies development: slow progress and promising prospect. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1265293	3.7	68
27	Performance-Based Risk-Sharing Arrangements: An Updated International Review. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 1063-1072	4.4	54
26	Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention. <i>Medical Decision Making</i> , <b>2017</b> , 37, 759-769	2.5	2
25	Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 171	5.6	70
24	Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, 1084-1090	1.9	2
23	The Australian Managed Entry Scheme: Are We Getting it Right?. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 555-565	4.4	9
22	Funding breakthrough therapies: A systematic review and recommendation. <i>Health Policy</i> , <b>2018</b> , 122, 217-229	3.2	22

21	Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends. <i>PharmacoEconomics - Open</i> , <b>2018</b> , 2, 109-123	2.1	19
20	Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 280	5.6	34
19	Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?. <i>Value in Health</i> , <b>2019</b> , 22, 677-683	3.3	15
18	Are Global Health Systems Ready for Transformative Therapies?. <i>Value in Health</i> , <b>2019</b> , 22, 627-641	3.3	14
17	Improving Access to High-Cost Technologies in the Asia Region. <i>International Journal of Technology Assessment in Health Care</i> , <b>2019</b> , 35, 168-175	1.8	2
16	Defining and Managing High-Priced Cures: Healthcare Payers' Opinions. <i>Value in Health</i> , <b>2019</b> , 22, 648-655,	3.5	3
15	Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. <i>European Journal of Health Economics</i> , <b>2019</b> , 20, 427-438	3.6	53
14	Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	2
13	HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. <i>European Journal of Health Economics</i> , <b>2020</b> , 21, 1421-1437	3.6	21
12	Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 594446	5.6	8
11	Reimbursement and Payment Models for Therapies With Transformative and Curative Intent. <b>2020</b> , 705-745		
10	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 21, 527-540	2.2	11
9	The Amortization of Funding Gene Therapies: Making the Intangibles Tangible for Patients.		
8	Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. <i>Health Services and Delivery Research</i> , <b>2017</b> , 5, 1-150	1.5	10
7	The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. <i>Health Technology Assessment</i> , <b>2017</b> , 21, 1-204	4.4	75
6	Investing in Health Care, Research and the Value of Information. <b>2015</b> , 177-198		
5	A Conceptual Framework for Life-Cycle Health Technology Assessment. <i>Value in Health</i> , <b>2022</b> ,	3.3	1
4	Performance-based risk-sharing arrangements for devices and procedures in cardiac electrophysiology: an innovative perspective.. <i>Europace</i> , <b>2022</b> ,	3.9	1

3 table1.docx. **2020**,

2 table2.docx. **2020**,

1 Designing Islamic Religious Education Teaching Based on Digital Innovation Creativity at Universitas Islam Negeri Antasari Banjarmasin. **2022**, 7, 344-354

0